Related Experiment Videos
CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia
J Dürig1, M Naschar, U Schmücker
1Department of Haematology, Medical Faculty, University of Essen, Essen, Germany.
Leukemia
|February 13, 2002
Summary
CD38 surface expression predicts clinical outcome in B-chronic lymphocytic leukaemia (B-CLL). CD38-positive B-CLL patients face a poorer prognosis, while CD38-negative patients experience longer survival and require less treatment.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- B-chronic lymphocytic leukaemia (B-CLL) is a heterogeneous lymphoid malignancy.
- Identifying prognostic markers is crucial for effective patient management.
Purpose of the Study:
- To investigate the role of CD38 surface expression as a prognostic marker in B-CLL patients.
- To correlate CD38 expression levels with clinical and laboratory parameters.
Main Methods:
- A multicolour flow cytometry assay was used to analyze CD38 surface expression in 133 B-CLL cases.
- Patients were categorized into CD38-positive (>= 20%) and CD38-negative (< 20%) subgroups.
- Clinical and laboratory parameters were analyzed in relation to CD38 expression.
Main Results:
- CD38-positive patients (n=56) exhibited an unfavorable clinical course, including advanced disease stage, poor chemotherapy response, and shorter survival.
- CD38-negative patients (n=77) required minimal treatment, had longer treatment-free periods, and showed prolonged survival (P < 0.05).
- CD38 expression was a stable marker, unaffected by chemotherapy in most patients.
Conclusions:
- CD38 surface expression is a robust predictor of clinical outcome in B-CLL.
- CD38 positivity indicates a more aggressive disease course and poorer prognosis.
- CD38 negativity is associated with a favorable prognosis and indolent disease.